—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Caris Life Sciences, Inc. Common Stock（CAI）— 同类公司组

数据截至2026-10-07 — 评分每个交易日晚间重新计算。分组标准＝首先为共同的Closelook指数成分，其次为行业。Closelook研究日记，不构成投资建议。

Caris Life Sciences, Inc. Common Stock的Closelook综合评分为59/100，在同类公司组内排名第5位（共7家）——组内评分最高的是BB Biotech AG（74/100）。

名称综合动量质量估值信号距52周高点
CAI Caris Life Sciences, Inc. Common Stock59796226ok19.5%
BION.SW BB Biotech AG74639681info12.3%
ONC BeiGene, Ltd.64816532ok5.5%
PTGX Protagonist Therapeutics Inc60776212info12.4%
REGN Regeneron Pharmaceuticals Inc60607252watch14%
CORT Corcept Therapeutics Incorporated57965024ok5.4%
TGTX TG Therapeutics Inc54706829info10.7%

评分为Closelook全部覆盖范围内的相对读数——方法论见公司评分说明。信号灯来自每日夜间信号看板。

FAQ · from the current data · as of 2026-10-07

Quick answers

Caris Life Sciences, Inc. Common Stock在Closelook覆盖范围内的同类公司有哪些？

分组首先基于共同的Closelook指数成分，其次基于行业：BB Biotech AG (BION.SW)、BeiGene, Ltd. (ONC)、Protagonist Therapeutics Inc (PTGX)、Regeneron Pharmaceuticals Inc (REGN)、Corcept Therapeutics Incorporated (CORT)、TG Therapeutics Inc (TGTX)。

CAI相对同类公司的评分如何？

Caris Life Sciences, Inc. Common Stock的综合评分为59/100，组内排名第5位（共7家），截至2026-10-07；组内最高综合评分为BB Biotech AG（74/100）。Closelook评分为研究日记读数，不构成评级或投资建议。

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.